SEND NEWS ARTICLE TO FRIEND
To Email:
From Email:
News Headline
Alnylam Pharmaceuticals Presents Complete Results from Phase IIb Trial with ALN-RSV01, an Inhaled RNAi Therapeutic for the Treatment of Respiratory Syncytial Virus (RSV) Infection